Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
furosemide + digoxin is an experimental combination therapy being evaluated for the intralesional treatment of cutaneous warts. Developed by researchers at Benha University, this formulation combines furosemide, a loop diuretic that inhibits the Na+/K+/2Cl- cotransporter (NKCC), and digoxin, a cardiac glycoside that inhibits the Na+/K+-ATPase pump. The therapeutic rationale involves the disruption of intracellular ionic balance within human papillomavirus (HPV)-infected keratinocytes. By altering the concentrations of sodium, potassium, and chloride, the combination is hypothesized to induce cellular stress and apoptosis or interfere with viral replication and assembly, providing a localized alternative to traditional destructive or immunomodulatory wart treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + digoxin.